Download the format to request laboratory tests

(for international use only)

ARTICLES OF INTEREST

TBRF ImmunoBlot

IgM and IgG

 

Now approved by New York State

Department of Health

 

PURPOSE

 

Borreliosis is caused by two groups of Borrelia:

B. burgdorferi group and the Tick-Borne Relapsing Fever (TBRF) Borrelia group. It was believed that B. burgdorferi group is the only group that causes Lyme-like symptoms.

Lyme ImmunoBlot

IgM and IgG

 

Now Approved by New York State

Department of Health

 

PURPOSE

 

Although IGeneX Lyme Western blot prepared from Borrelia burgdorferi (BB) strains B31 and 297 is one of the most sensitive test to detect B. burgdorferi specific antibodies in human serum, it does not detect antibodies to all the BB antigens.

Bartonella

Multi-Species Western Blot

IgM and IgG

 

PURPOSE

 

The Bartonella IgM and IgG Western Blots are designed to detect IgM and IgG antibodies to Bartonella species including Bartonella henselae, B. quintana, B. elizabethae and B. vinsonii antigens in serum of patients suspected of having Bartonella infection.

Broad Coverage

Ab Assay

Lyme and TBRF

 

PURPOSE

 

Borreliosis, a vector-borne disease caused by a bacterium-Borrelia: The Lyme Borreliae group and the Tick-Borne Relapsing Fever (TBRF) Borreliae group. The Lyme Borreliae group is transmitted by hard ticks (Ixodes)

and the TBRF Borreliae group is transmitted by hard  (Ixodes) and soft (Ornithodorus) ticks.

The IGeneX Advantage

Test with confidence

 

 

 

 

For over 25 years, IGeneX has been at the forefront of diagnostic testing for Lyme disease and several other tick-borne diseases. In recent years, IGeneX has continued to lead the way on Borreliosis (Lyme and Tick-borne Relapsing Fever) testing through continued research and development from a dedicated team of tick-borne disease experts.

Lyme IgXSpot

 

PURPOSE

 

This test is recommended for detection of very early and/ or late detection of B. burgdorferi infection. For diagnostic purposes, the IgXSpot test results should be used in conjunction with clinical symptoms and other evidence available to the diagnosing physician.

CENAREM 2020